You have 9 free searches left this month | for more free features.

anti-PD1

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

    Not yet recruiting
    • Stage IIIA Hepatocellular Carcinoma
    • Radiotherapy combined with TKI and Anti-PD-1 Antibody
    • (no location specified)
    Sep 24, 2023

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?

    Not yet recruiting
    • Locally Advanced Rectal Cancer
    • +2 more
    • nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
    • Changchun, Ji Lin, China
      First Hospital of Jilin University
    Aug 11, 2023

    Immunotherapy, ADR Trial in Beijing

    Not yet recruiting
    • Immunotherapy
    • ADR
      • Beijing, Beijing, China
        Xuanwu Hospital
      Jan 27, 2023

      Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

      Not yet recruiting
      • Lung Neoplasm
      • +2 more
      • Tumor samples
      • Bordeaux, France
        CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
      Aug 28, 2023

      Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

      Recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Zhongshan Hospital Fudan university
      Jan 31, 2023

      Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

      Not yet recruiting
      • Solid Tumor, Adult
      • +2 more
      • (no location specified)
      Dec 14, 2022

      Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Neoadjuvant Chemoimmunotherapy
      • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
      • (no location specified)
      Feb 14, 2023

      Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Oligometastatic Disease
      • PD-1 combined with SBRT
      • Guangzhou, Guangdong, China
        Mian Xi
      Dec 18, 2022

      Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • Low-Dose Decitabine plus anti-PD-1
      • Beijing, Beijing, China
        ChinaPLAGH
      Apr 18, 2023

      Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

      Not yet recruiting
      • Colorectal Cancer
      • Serplulimab + FOLFOXIRI
      • Radiation therapy
      • (no location specified)
      Oct 24, 2023

      Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

      Recruiting
      • Oral Squamous Cell Carcinoma
      • +3 more
      • Camrelizumab (anti-PD-1 inhibitor)
      • Apatinib (anti-VEGFR inhibitor)
      • Shanghai, Shanghai, China
        Ninth People's Hospital, Shanghai Jiao Tong University School of
      Oct 8, 2022

      Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

      Not yet recruiting
      • Hepatocellular Carcinoma Non-resectable
      • transarterial therapies
      • (no location specified)
      Nov 27, 2022

      Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

      Not yet recruiting
      • Esophagus Cancer
      • +4 more
      • Intravenous injection of P-IL-2
      • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
      • (no location specified)
      Apr 24, 2023

      Generation ofArtificial Intelligence Algorithm Based on Analysis

      Not yet recruiting
      • Metastatic Melanoma
      • Photo
      • (no location specified)
      May 3, 2023

      NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • Alirocumab and Cemiplimab
      • (no location specified)
      Jan 31, 2023

      Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

      Recruiting
      • Melanoma (Skin)
      • +4 more
      • Bloomington, Minnesota
      • +7 more
      Jan 31, 2023

      Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

      Not yet recruiting
      • Colorectal Cancer
      • Hangzhou, Zhejiang, China
        Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
      Jan 30, 2023

      Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

      Recruiting
      • Hepatocellular Carcinoma
      • Beijing, Beijing, China
        Beijing Tsinghua Changgung Hospital
      Jan 5, 2023

      NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)

      Terminated
      • Non-Small Cell Lung Cancer
      • Immunotherapy
      • Ann Arbor, Michigan
        VA Ann Arbor Healthcare System, Ann Arbor, MI
      Jan 6, 2023

      Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

      Not yet recruiting
      • Pancreatic Ductal Adenocarcinoma
      • Refractory Non-Small Cell Lung Cancer
      • Washington, District of Columbia
        Georgetown Lombardi Comprehensive Cancer Center
      Sep 1, 2023

      Hepatocellular Carcinoma, HCC, Liver Cancer Trial in Hong Kong (Nivolumab, Hepatectomy)

      Completed
      • Hepatocellular Carcinoma
      • +2 more
      • Hong Kong, Hong Kong
        Queen Mary Hospital
      Jul 20, 2022

      Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

      Recruiting
      • Advanced Solid Tumors
      • Metastatic Solid Tumors
      • Lyon, France
        Centre Léon Bérard
      Nov 30, 2022